Treatment with long-acting muscarinic antagonists (LAMA) plus long-acting β-agonists (LABA) is associated with fewer exacerbation events in patients with chronic obstructive pulmonary disease (COPD) ...

They performed a cohort study using commercial claims, with the goal of comparing COPD exacerbation and pneumonia hospitalization of patients started on LAMA-LABA inhalers vs ICS-LABA inhalers.

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.

The researchers found that in patients with COPD, new LABA and LAMA use was associated with a 1.5- and 1.52-fold increased cardiovascular risk within 30 days of initiation, respectively; with ...

They were allowed to be on monotherapy or dual therapy during the year before cohort entry, but were excluded if they had received either study inhaler or an inhaled corticosteroid-LAMA-LABA ...

This new fixed-dose combination of a LABA and a LAMA was more effective in reducing COPD exacerbations and only has to be administered once daily.

BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients started a new inhaled treatment in 2022, according to a presentation at the ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized ...

In COPD, Hospitalization Can Trigger Inhaler Discontinuation —Standardized practices are needed to prevent patients from either not receiving or stopping their medication on discharge after ...

With the 2023 Report, GOLD no longer encourages the use of a LABA/inhaled corticosteroid (ICS) combination in COPD. The new 2023 GOLD recommendations represent a meaningful change for the treatment of ...

A long-acting muscarinic antagonist plus long-acting beta agonist (LABA) was linked to fewer COPD exacerbations and pneumonia hospitalizations vs. an inhaled corticosteroid and LABA, according to ...